Global Multiple Sclerosis Market

Multiple Sclerosis Comprehensive Study by Type (Clinically Isolated Syndrome, Relapsing-remitting, Secondary progressive, Primary progressive, Progressive-relapsing), Distribution Channel (Hospitals & Clinics, Specialty Pharmacy, Retail Pharmacy, Online Pharmacy), Treatment Type (Rehabilitation and Physical Therapy, Plasma Exchange, Stem Cell Therapy, Medications (Injectable Medications, Oral Medications, Infused Medications), Others), Drug Class (Immunomodulator, Immunosuppressant, Interferons, Others) Players and Region - Global Market Outlook to 2029

Multiple Sclerosis Market by XX Submarkets | Forecast Years 2024-2029 | CAGR: 4.5%  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
About Multiple Sclerosis
Multiple sclerosis is a long-lasting (chronic) disease of the central nervous system. It is thought to be an autoimmune disorder, a condition in which the body attacks itself by mistake. It is an unpredictable disease that affects people differently. Some people with Multiple sclerosis may have only mild symptoms. Others may lose their ability to see clearly, write, speak, or walk when communication between the brain and other parts of the body becomes disrupted. It is characterized by inflammation, demyelination and degenerative changes progressive changes and primary progressive brain and spinal cord atrophy along with neuroaxonal loss. Rise in number of R&D activities of pharmaceutical companies. High-Cost Initiate with therapeutics and side effects of drug may hamper the growth factor. The increasing prevalence of this replacing remitting and primary progressive Multiple sclerosis disease has increased the demand of effective diagnosis and treatment of multiple sclerosis globally. Hence these government are actively supporting the treatment of sclerosis.

AttributesDetails
Study Period2019-2029
Base Year2023
UnitValue (USD Million)
CAGR4.5%


The competitive landscape in the Multiple Sclerosis market is constantly evolving, driven by innovative research, evolving treatment approaches, and the growing need for affordable and accessible therapies. As new players emerge and established companies refine their offerings, the market is poised for continued growth and advancements in MS treatment, ultimately benefiting patients by providing them with more effective options to manage their condition. Analyst at AMA Research estimates that United States Players will contribute the maximum growth to Global Multiple Sclerosis market throughout the forecasted period. Established and emerging Players should take a closer view at their existing organizations and reinvent traditional business and operating models to adapt to the future.

Roche Holding AG(Switzerland), Biogen Inc. (United States), Novartis AG (Switzerland), Teva Pharmaceutical Industries Ltd. (Israel), Elan Corporation plc (Ireland), Johnson & Johnson Services, Inc (United States), AbbVie Inc. (United States), Mitsubishi Tanabe Pharma Corporation (Japan), Sanofi (France) and Merck KGaA (Germany) are some of the key players that are part of study coverage. Additionally, the Players which are also part of the research coverage are Siemens Healthineers (Germany), EMD Serono (United States), Philips Healthcare (Netherlands), Bio-Rad Laboratories, Inc. (United States), LabCorp (United States) and Rehman Technology Consulting, LLC (United States).

Segmentation Overview
AMA Research has segmented the market of Global Multiple Sclerosis market by Type (Clinically Isolated Syndrome, Relapsing-remitting, Secondary progressive, Primary progressive and Progressive-relapsing) and Region.



On the basis of geography, the market of Multiple Sclerosis has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). If we see Market by Distribution Channel, the sub-segment i.e. Hospitals & Clinics will boost the Multiple Sclerosis market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Treatment Type, the sub-segment i.e. Rehabilitation and Physical Therapy will boost the Multiple Sclerosis market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Drug Class, the sub-segment i.e. Immunomodulator will boost the Multiple Sclerosis market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Influencing Trend:
Growing Role of Artificial Intelligence in medical data, predicting disease progression, and identifying potential drug targets.

Market Growth Drivers:
Increasing Prevalence of Multiple Sclerosis and Rising public awareness and advocacy efforts by patient organizations and healthcare professionals

Challenges:
Complexities of Diagnosis

Restraints:
Shortage of qualified Workers.

Opportunities:
Technological Advancement in Multiple Sclerosis such as MRI techniques, Biomarker Analysis, and Digital Health Tools. and Increased Number of Research and Development Activities.

Market Leaders and their expansionary development strategies
In September 2023, EMD Serono, the specialty care business of Merck KGaA, Darmstadt, Germany, partners with Teva Pharmaceuticals to expand access to its MS treatment cladribine (Mavenclad) in various countries across Europe. This partnership aimed to increase patient access to this established therapy in new markets.
In October 2023, The European Medicines Agency grants marketing authorization for omsaponin (Zeposia), an oral S1P modulator from Novartis, for the treatment of relapsing forms of MS. This expands access to this established therapy in Europe, offering another oral treatment option for patients.
FDA guidelines emphasize patient safety and ethical considerations throughout the trial design. Specific protocols are outlined for different phases of clinical trials (Phase I, II, III) for MS drugs., CDSCO guidelines closely align with international standards for Good Clinical Practice to ensure ethical and scientific rigor in MS clinical trials conducted in India. and EMA emphasizes pharmacovigilance, the ongoing monitoring of drug safety even after market approval, to ensure patient safety throughout the drug's lifecycle.

Key Target Audience
Healthcare Professionals, Government and Regulatory Bodies, Potential Investors, Research and Development Organization and Others

About Approach
To evaluate and validate the market size various sources including primary and secondary analysis is utilized. AMA Research follows regulatory standards such as NAICS/SIC/ICB/TRCB, to have a better understanding of the market. The market study is conducted on basis of more than 200 companies dealing in the market regional as well as global areas with the purpose to understand the companies positioning regarding the market value, volume, and their market share for regional as well as global.

Further to bring relevance specific to any niche market we set and apply a number of criteria like Geographic Footprints, Regional Segments of Revenue, Operational Centres, etc. The next step is to finalize a team (In-House + Data Agencies) who then starts collecting C & D level executives and profiles, Industry experts, Opinion leaders, etc., and work towards appointment generation.

The primary research is performed by taking the interviews of executives of various companies dealing in the market as well as using the survey reports, research institute, and latest research reports. Meanwhile, the analyst team keeps preparing a set of questionnaires, and after getting the appointee list; the target audience is then tapped and segregated with various mediums and channels that are feasible for making connections that including email communication, telephonic, skype, LinkedIn Group & InMail, Community Forums, Community Forums, open Survey, SurveyMonkey, etc.

Report Objectives / Segmentation Covered

By Type
  • Clinically Isolated Syndrome
  • Relapsing-remitting
  • Secondary progressive
  • Primary progressive
  • Progressive-relapsing
By Distribution Channel
  • Hospitals & Clinics
  • Specialty Pharmacy
  • Retail Pharmacy
  • Online Pharmacy

By Treatment Type
  • Rehabilitation and Physical Therapy
  • Plasma Exchange
  • Stem Cell Therapy
  • Medications (Injectable Medications, Oral Medications, Infused Medications)
  • Others

By Drug Class
  • Immunomodulator
  • Immunosuppressant
  • Interferons
  • Others

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increasing Prevalence of Multiple Sclerosis
      • 3.2.2. Rising public awareness and advocacy efforts by patient organizations and healthcare professionals
    • 3.3. Market Challenges
      • 3.3.1. Complexities of Diagnosis
    • 3.4. Market Trends
      • 3.4.1. Growing Role of Artificial Intelligence in medical data, predicting disease progression, and identifying potential drug targets.
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Multiple Sclerosis, by Type, Distribution Channel, Treatment Type, Drug Class and Region (value) (2018-2023)
    • 5.1. Introduction
    • 5.2. Global Multiple Sclerosis (Value)
      • 5.2.1. Global Multiple Sclerosis by: Type (Value)
        • 5.2.1.1. Clinically Isolated Syndrome
        • 5.2.1.2. Relapsing-remitting
        • 5.2.1.3. Secondary progressive
        • 5.2.1.4. Primary progressive
        • 5.2.1.5. Progressive-relapsing
      • 5.2.2. Global Multiple Sclerosis by: Distribution Channel (Value)
        • 5.2.2.1. Hospitals & Clinics
        • 5.2.2.2. Specialty Pharmacy
        • 5.2.2.3. Retail Pharmacy
        • 5.2.2.4. Online Pharmacy
      • 5.2.3. Global Multiple Sclerosis by: Treatment Type (Value)
        • 5.2.3.1. Rehabilitation and Physical Therapy
        • 5.2.3.2. Plasma Exchange
        • 5.2.3.3. Stem Cell Therapy
        • 5.2.3.4. Medications (Injectable Medications, Oral Medications, Infused Medications)
        • 5.2.3.5. Others
      • 5.2.4. Global Multiple Sclerosis by: Drug Class (Value)
        • 5.2.4.1. Immunomodulator
        • 5.2.4.2. Immunosuppressant
        • 5.2.4.3. Interferons
        • 5.2.4.4. Others
      • 5.2.5. Global Multiple Sclerosis Region
        • 5.2.5.1. South America
          • 5.2.5.1.1. Brazil
          • 5.2.5.1.2. Argentina
          • 5.2.5.1.3. Rest of South America
        • 5.2.5.2. Asia Pacific
          • 5.2.5.2.1. China
          • 5.2.5.2.2. Japan
          • 5.2.5.2.3. India
          • 5.2.5.2.4. South Korea
          • 5.2.5.2.5. Taiwan
          • 5.2.5.2.6. Australia
          • 5.2.5.2.7. Rest of Asia-Pacific
        • 5.2.5.3. Europe
          • 5.2.5.3.1. Germany
          • 5.2.5.3.2. France
          • 5.2.5.3.3. Italy
          • 5.2.5.3.4. United Kingdom
          • 5.2.5.3.5. Netherlands
          • 5.2.5.3.6. Rest of Europe
        • 5.2.5.4. MEA
          • 5.2.5.4.1. Middle East
          • 5.2.5.4.2. Africa
        • 5.2.5.5. North America
          • 5.2.5.5.1. United States
          • 5.2.5.5.2. Canada
          • 5.2.5.5.3. Mexico
  • 6. Multiple Sclerosis: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2023)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Roche Holding AG(Switzerland)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Biogen Inc. (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Novartis AG (Switzerland)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Teva Pharmaceutical Industries Ltd. (Israel)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Elan Corporation plc (Ireland)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Johnson & Johnson Services, Inc (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. AbbVie Inc. (United States)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Mitsubishi Tanabe Pharma Corporation (Japan)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Sanofi (France)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Merck KGaA (Germany)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Multiple Sclerosis Sale, by Type, Distribution Channel, Treatment Type, Drug Class and Region (value) (2024-2029)
    • 7.1. Introduction
    • 7.2. Global Multiple Sclerosis (Value)
      • 7.2.1. Global Multiple Sclerosis by: Type (Value)
        • 7.2.1.1. Clinically Isolated Syndrome
        • 7.2.1.2. Relapsing-remitting
        • 7.2.1.3. Secondary progressive
        • 7.2.1.4. Primary progressive
        • 7.2.1.5. Progressive-relapsing
      • 7.2.2. Global Multiple Sclerosis by: Distribution Channel (Value)
        • 7.2.2.1. Hospitals & Clinics
        • 7.2.2.2. Specialty Pharmacy
        • 7.2.2.3. Retail Pharmacy
        • 7.2.2.4. Online Pharmacy
      • 7.2.3. Global Multiple Sclerosis by: Treatment Type (Value)
        • 7.2.3.1. Rehabilitation and Physical Therapy
        • 7.2.3.2. Plasma Exchange
        • 7.2.3.3. Stem Cell Therapy
        • 7.2.3.4. Medications (Injectable Medications, Oral Medications, Infused Medications)
        • 7.2.3.5. Others
      • 7.2.4. Global Multiple Sclerosis by: Drug Class (Value)
        • 7.2.4.1. Immunomodulator
        • 7.2.4.2. Immunosuppressant
        • 7.2.4.3. Interferons
        • 7.2.4.4. Others
      • 7.2.5. Global Multiple Sclerosis Region
        • 7.2.5.1. South America
          • 7.2.5.1.1. Brazil
          • 7.2.5.1.2. Argentina
          • 7.2.5.1.3. Rest of South America
        • 7.2.5.2. Asia Pacific
          • 7.2.5.2.1. China
          • 7.2.5.2.2. Japan
          • 7.2.5.2.3. India
          • 7.2.5.2.4. South Korea
          • 7.2.5.2.5. Taiwan
          • 7.2.5.2.6. Australia
          • 7.2.5.2.7. Rest of Asia-Pacific
        • 7.2.5.3. Europe
          • 7.2.5.3.1. Germany
          • 7.2.5.3.2. France
          • 7.2.5.3.3. Italy
          • 7.2.5.3.4. United Kingdom
          • 7.2.5.3.5. Netherlands
          • 7.2.5.3.6. Rest of Europe
        • 7.2.5.4. MEA
          • 7.2.5.4.1. Middle East
          • 7.2.5.4.2. Africa
        • 7.2.5.5. North America
          • 7.2.5.5.1. United States
          • 7.2.5.5.2. Canada
          • 7.2.5.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Multiple Sclerosis: by Type(USD Million)
  • Table 2. Multiple Sclerosis Clinically Isolated Syndrome , by Region USD Million (2018-2023)
  • Table 3. Multiple Sclerosis Relapsing-remitting , by Region USD Million (2018-2023)
  • Table 4. Multiple Sclerosis Secondary progressive , by Region USD Million (2018-2023)
  • Table 5. Multiple Sclerosis Primary progressive , by Region USD Million (2018-2023)
  • Table 6. Multiple Sclerosis Progressive-relapsing , by Region USD Million (2018-2023)
  • Table 7. Multiple Sclerosis: by Distribution Channel(USD Million)
  • Table 8. Multiple Sclerosis Hospitals & Clinics , by Region USD Million (2018-2023)
  • Table 9. Multiple Sclerosis Specialty Pharmacy , by Region USD Million (2018-2023)
  • Table 10. Multiple Sclerosis Retail Pharmacy , by Region USD Million (2018-2023)
  • Table 11. Multiple Sclerosis Online Pharmacy , by Region USD Million (2018-2023)
  • Table 12. Multiple Sclerosis: by Treatment Type(USD Million)
  • Table 13. Multiple Sclerosis Rehabilitation and Physical Therapy , by Region USD Million (2018-2023)
  • Table 14. Multiple Sclerosis Plasma Exchange , by Region USD Million (2018-2023)
  • Table 15. Multiple Sclerosis Stem Cell Therapy , by Region USD Million (2018-2023)
  • Table 16. Multiple Sclerosis Medications (Injectable Medications, Oral Medications, Infused Medications) , by Region USD Million (2018-2023)
  • Table 17. Multiple Sclerosis Others , by Region USD Million (2018-2023)
  • Table 18. Multiple Sclerosis: by Drug Class(USD Million)
  • Table 19. Multiple Sclerosis Immunomodulator , by Region USD Million (2018-2023)
  • Table 20. Multiple Sclerosis Immunosuppressant , by Region USD Million (2018-2023)
  • Table 21. Multiple Sclerosis Interferons , by Region USD Million (2018-2023)
  • Table 22. Multiple Sclerosis Others , by Region USD Million (2018-2023)
  • Table 23. South America Multiple Sclerosis, by Country USD Million (2018-2023)
  • Table 24. South America Multiple Sclerosis, by Type USD Million (2018-2023)
  • Table 25. South America Multiple Sclerosis, by Distribution Channel USD Million (2018-2023)
  • Table 26. South America Multiple Sclerosis, by Treatment Type USD Million (2018-2023)
  • Table 27. South America Multiple Sclerosis, by Drug Class USD Million (2018-2023)
  • Table 28. Brazil Multiple Sclerosis, by Type USD Million (2018-2023)
  • Table 29. Brazil Multiple Sclerosis, by Distribution Channel USD Million (2018-2023)
  • Table 30. Brazil Multiple Sclerosis, by Treatment Type USD Million (2018-2023)
  • Table 31. Brazil Multiple Sclerosis, by Drug Class USD Million (2018-2023)
  • Table 32. Argentina Multiple Sclerosis, by Type USD Million (2018-2023)
  • Table 33. Argentina Multiple Sclerosis, by Distribution Channel USD Million (2018-2023)
  • Table 34. Argentina Multiple Sclerosis, by Treatment Type USD Million (2018-2023)
  • Table 35. Argentina Multiple Sclerosis, by Drug Class USD Million (2018-2023)
  • Table 36. Rest of South America Multiple Sclerosis, by Type USD Million (2018-2023)
  • Table 37. Rest of South America Multiple Sclerosis, by Distribution Channel USD Million (2018-2023)
  • Table 38. Rest of South America Multiple Sclerosis, by Treatment Type USD Million (2018-2023)
  • Table 39. Rest of South America Multiple Sclerosis, by Drug Class USD Million (2018-2023)
  • Table 40. Asia Pacific Multiple Sclerosis, by Country USD Million (2018-2023)
  • Table 41. Asia Pacific Multiple Sclerosis, by Type USD Million (2018-2023)
  • Table 42. Asia Pacific Multiple Sclerosis, by Distribution Channel USD Million (2018-2023)
  • Table 43. Asia Pacific Multiple Sclerosis, by Treatment Type USD Million (2018-2023)
  • Table 44. Asia Pacific Multiple Sclerosis, by Drug Class USD Million (2018-2023)
  • Table 45. China Multiple Sclerosis, by Type USD Million (2018-2023)
  • Table 46. China Multiple Sclerosis, by Distribution Channel USD Million (2018-2023)
  • Table 47. China Multiple Sclerosis, by Treatment Type USD Million (2018-2023)
  • Table 48. China Multiple Sclerosis, by Drug Class USD Million (2018-2023)
  • Table 49. Japan Multiple Sclerosis, by Type USD Million (2018-2023)
  • Table 50. Japan Multiple Sclerosis, by Distribution Channel USD Million (2018-2023)
  • Table 51. Japan Multiple Sclerosis, by Treatment Type USD Million (2018-2023)
  • Table 52. Japan Multiple Sclerosis, by Drug Class USD Million (2018-2023)
  • Table 53. India Multiple Sclerosis, by Type USD Million (2018-2023)
  • Table 54. India Multiple Sclerosis, by Distribution Channel USD Million (2018-2023)
  • Table 55. India Multiple Sclerosis, by Treatment Type USD Million (2018-2023)
  • Table 56. India Multiple Sclerosis, by Drug Class USD Million (2018-2023)
  • Table 57. South Korea Multiple Sclerosis, by Type USD Million (2018-2023)
  • Table 58. South Korea Multiple Sclerosis, by Distribution Channel USD Million (2018-2023)
  • Table 59. South Korea Multiple Sclerosis, by Treatment Type USD Million (2018-2023)
  • Table 60. South Korea Multiple Sclerosis, by Drug Class USD Million (2018-2023)
  • Table 61. Taiwan Multiple Sclerosis, by Type USD Million (2018-2023)
  • Table 62. Taiwan Multiple Sclerosis, by Distribution Channel USD Million (2018-2023)
  • Table 63. Taiwan Multiple Sclerosis, by Treatment Type USD Million (2018-2023)
  • Table 64. Taiwan Multiple Sclerosis, by Drug Class USD Million (2018-2023)
  • Table 65. Australia Multiple Sclerosis, by Type USD Million (2018-2023)
  • Table 66. Australia Multiple Sclerosis, by Distribution Channel USD Million (2018-2023)
  • Table 67. Australia Multiple Sclerosis, by Treatment Type USD Million (2018-2023)
  • Table 68. Australia Multiple Sclerosis, by Drug Class USD Million (2018-2023)
  • Table 69. Rest of Asia-Pacific Multiple Sclerosis, by Type USD Million (2018-2023)
  • Table 70. Rest of Asia-Pacific Multiple Sclerosis, by Distribution Channel USD Million (2018-2023)
  • Table 71. Rest of Asia-Pacific Multiple Sclerosis, by Treatment Type USD Million (2018-2023)
  • Table 72. Rest of Asia-Pacific Multiple Sclerosis, by Drug Class USD Million (2018-2023)
  • Table 73. Europe Multiple Sclerosis, by Country USD Million (2018-2023)
  • Table 74. Europe Multiple Sclerosis, by Type USD Million (2018-2023)
  • Table 75. Europe Multiple Sclerosis, by Distribution Channel USD Million (2018-2023)
  • Table 76. Europe Multiple Sclerosis, by Treatment Type USD Million (2018-2023)
  • Table 77. Europe Multiple Sclerosis, by Drug Class USD Million (2018-2023)
  • Table 78. Germany Multiple Sclerosis, by Type USD Million (2018-2023)
  • Table 79. Germany Multiple Sclerosis, by Distribution Channel USD Million (2018-2023)
  • Table 80. Germany Multiple Sclerosis, by Treatment Type USD Million (2018-2023)
  • Table 81. Germany Multiple Sclerosis, by Drug Class USD Million (2018-2023)
  • Table 82. France Multiple Sclerosis, by Type USD Million (2018-2023)
  • Table 83. France Multiple Sclerosis, by Distribution Channel USD Million (2018-2023)
  • Table 84. France Multiple Sclerosis, by Treatment Type USD Million (2018-2023)
  • Table 85. France Multiple Sclerosis, by Drug Class USD Million (2018-2023)
  • Table 86. Italy Multiple Sclerosis, by Type USD Million (2018-2023)
  • Table 87. Italy Multiple Sclerosis, by Distribution Channel USD Million (2018-2023)
  • Table 88. Italy Multiple Sclerosis, by Treatment Type USD Million (2018-2023)
  • Table 89. Italy Multiple Sclerosis, by Drug Class USD Million (2018-2023)
  • Table 90. United Kingdom Multiple Sclerosis, by Type USD Million (2018-2023)
  • Table 91. United Kingdom Multiple Sclerosis, by Distribution Channel USD Million (2018-2023)
  • Table 92. United Kingdom Multiple Sclerosis, by Treatment Type USD Million (2018-2023)
  • Table 93. United Kingdom Multiple Sclerosis, by Drug Class USD Million (2018-2023)
  • Table 94. Netherlands Multiple Sclerosis, by Type USD Million (2018-2023)
  • Table 95. Netherlands Multiple Sclerosis, by Distribution Channel USD Million (2018-2023)
  • Table 96. Netherlands Multiple Sclerosis, by Treatment Type USD Million (2018-2023)
  • Table 97. Netherlands Multiple Sclerosis, by Drug Class USD Million (2018-2023)
  • Table 98. Rest of Europe Multiple Sclerosis, by Type USD Million (2018-2023)
  • Table 99. Rest of Europe Multiple Sclerosis, by Distribution Channel USD Million (2018-2023)
  • Table 100. Rest of Europe Multiple Sclerosis, by Treatment Type USD Million (2018-2023)
  • Table 101. Rest of Europe Multiple Sclerosis, by Drug Class USD Million (2018-2023)
  • Table 102. MEA Multiple Sclerosis, by Country USD Million (2018-2023)
  • Table 103. MEA Multiple Sclerosis, by Type USD Million (2018-2023)
  • Table 104. MEA Multiple Sclerosis, by Distribution Channel USD Million (2018-2023)
  • Table 105. MEA Multiple Sclerosis, by Treatment Type USD Million (2018-2023)
  • Table 106. MEA Multiple Sclerosis, by Drug Class USD Million (2018-2023)
  • Table 107. Middle East Multiple Sclerosis, by Type USD Million (2018-2023)
  • Table 108. Middle East Multiple Sclerosis, by Distribution Channel USD Million (2018-2023)
  • Table 109. Middle East Multiple Sclerosis, by Treatment Type USD Million (2018-2023)
  • Table 110. Middle East Multiple Sclerosis, by Drug Class USD Million (2018-2023)
  • Table 111. Africa Multiple Sclerosis, by Type USD Million (2018-2023)
  • Table 112. Africa Multiple Sclerosis, by Distribution Channel USD Million (2018-2023)
  • Table 113. Africa Multiple Sclerosis, by Treatment Type USD Million (2018-2023)
  • Table 114. Africa Multiple Sclerosis, by Drug Class USD Million (2018-2023)
  • Table 115. North America Multiple Sclerosis, by Country USD Million (2018-2023)
  • Table 116. North America Multiple Sclerosis, by Type USD Million (2018-2023)
  • Table 117. North America Multiple Sclerosis, by Distribution Channel USD Million (2018-2023)
  • Table 118. North America Multiple Sclerosis, by Treatment Type USD Million (2018-2023)
  • Table 119. North America Multiple Sclerosis, by Drug Class USD Million (2018-2023)
  • Table 120. United States Multiple Sclerosis, by Type USD Million (2018-2023)
  • Table 121. United States Multiple Sclerosis, by Distribution Channel USD Million (2018-2023)
  • Table 122. United States Multiple Sclerosis, by Treatment Type USD Million (2018-2023)
  • Table 123. United States Multiple Sclerosis, by Drug Class USD Million (2018-2023)
  • Table 124. Canada Multiple Sclerosis, by Type USD Million (2018-2023)
  • Table 125. Canada Multiple Sclerosis, by Distribution Channel USD Million (2018-2023)
  • Table 126. Canada Multiple Sclerosis, by Treatment Type USD Million (2018-2023)
  • Table 127. Canada Multiple Sclerosis, by Drug Class USD Million (2018-2023)
  • Table 128. Mexico Multiple Sclerosis, by Type USD Million (2018-2023)
  • Table 129. Mexico Multiple Sclerosis, by Distribution Channel USD Million (2018-2023)
  • Table 130. Mexico Multiple Sclerosis, by Treatment Type USD Million (2018-2023)
  • Table 131. Mexico Multiple Sclerosis, by Drug Class USD Million (2018-2023)
  • Table 132. Company Basic Information, Sales Area and Its Competitors
  • Table 133. Company Basic Information, Sales Area and Its Competitors
  • Table 134. Company Basic Information, Sales Area and Its Competitors
  • Table 135. Company Basic Information, Sales Area and Its Competitors
  • Table 136. Company Basic Information, Sales Area and Its Competitors
  • Table 137. Company Basic Information, Sales Area and Its Competitors
  • Table 138. Company Basic Information, Sales Area and Its Competitors
  • Table 139. Company Basic Information, Sales Area and Its Competitors
  • Table 140. Company Basic Information, Sales Area and Its Competitors
  • Table 141. Company Basic Information, Sales Area and Its Competitors
  • Table 142. Multiple Sclerosis: by Type(USD Million)
  • Table 143. Multiple Sclerosis Clinically Isolated Syndrome , by Region USD Million (2024-2029)
  • Table 144. Multiple Sclerosis Relapsing-remitting , by Region USD Million (2024-2029)
  • Table 145. Multiple Sclerosis Secondary progressive , by Region USD Million (2024-2029)
  • Table 146. Multiple Sclerosis Primary progressive , by Region USD Million (2024-2029)
  • Table 147. Multiple Sclerosis Progressive-relapsing , by Region USD Million (2024-2029)
  • Table 148. Multiple Sclerosis: by Distribution Channel(USD Million)
  • Table 149. Multiple Sclerosis Hospitals & Clinics , by Region USD Million (2024-2029)
  • Table 150. Multiple Sclerosis Specialty Pharmacy , by Region USD Million (2024-2029)
  • Table 151. Multiple Sclerosis Retail Pharmacy , by Region USD Million (2024-2029)
  • Table 152. Multiple Sclerosis Online Pharmacy , by Region USD Million (2024-2029)
  • Table 153. Multiple Sclerosis: by Treatment Type(USD Million)
  • Table 154. Multiple Sclerosis Rehabilitation and Physical Therapy , by Region USD Million (2024-2029)
  • Table 155. Multiple Sclerosis Plasma Exchange , by Region USD Million (2024-2029)
  • Table 156. Multiple Sclerosis Stem Cell Therapy , by Region USD Million (2024-2029)
  • Table 157. Multiple Sclerosis Medications (Injectable Medications, Oral Medications, Infused Medications) , by Region USD Million (2024-2029)
  • Table 158. Multiple Sclerosis Others , by Region USD Million (2024-2029)
  • Table 159. Multiple Sclerosis: by Drug Class(USD Million)
  • Table 160. Multiple Sclerosis Immunomodulator , by Region USD Million (2024-2029)
  • Table 161. Multiple Sclerosis Immunosuppressant , by Region USD Million (2024-2029)
  • Table 162. Multiple Sclerosis Interferons , by Region USD Million (2024-2029)
  • Table 163. Multiple Sclerosis Others , by Region USD Million (2024-2029)
  • Table 164. South America Multiple Sclerosis, by Country USD Million (2024-2029)
  • Table 165. South America Multiple Sclerosis, by Type USD Million (2024-2029)
  • Table 166. South America Multiple Sclerosis, by Distribution Channel USD Million (2024-2029)
  • Table 167. South America Multiple Sclerosis, by Treatment Type USD Million (2024-2029)
  • Table 168. South America Multiple Sclerosis, by Drug Class USD Million (2024-2029)
  • Table 169. Brazil Multiple Sclerosis, by Type USD Million (2024-2029)
  • Table 170. Brazil Multiple Sclerosis, by Distribution Channel USD Million (2024-2029)
  • Table 171. Brazil Multiple Sclerosis, by Treatment Type USD Million (2024-2029)
  • Table 172. Brazil Multiple Sclerosis, by Drug Class USD Million (2024-2029)
  • Table 173. Argentina Multiple Sclerosis, by Type USD Million (2024-2029)
  • Table 174. Argentina Multiple Sclerosis, by Distribution Channel USD Million (2024-2029)
  • Table 175. Argentina Multiple Sclerosis, by Treatment Type USD Million (2024-2029)
  • Table 176. Argentina Multiple Sclerosis, by Drug Class USD Million (2024-2029)
  • Table 177. Rest of South America Multiple Sclerosis, by Type USD Million (2024-2029)
  • Table 178. Rest of South America Multiple Sclerosis, by Distribution Channel USD Million (2024-2029)
  • Table 179. Rest of South America Multiple Sclerosis, by Treatment Type USD Million (2024-2029)
  • Table 180. Rest of South America Multiple Sclerosis, by Drug Class USD Million (2024-2029)
  • Table 181. Asia Pacific Multiple Sclerosis, by Country USD Million (2024-2029)
  • Table 182. Asia Pacific Multiple Sclerosis, by Type USD Million (2024-2029)
  • Table 183. Asia Pacific Multiple Sclerosis, by Distribution Channel USD Million (2024-2029)
  • Table 184. Asia Pacific Multiple Sclerosis, by Treatment Type USD Million (2024-2029)
  • Table 185. Asia Pacific Multiple Sclerosis, by Drug Class USD Million (2024-2029)
  • Table 186. China Multiple Sclerosis, by Type USD Million (2024-2029)
  • Table 187. China Multiple Sclerosis, by Distribution Channel USD Million (2024-2029)
  • Table 188. China Multiple Sclerosis, by Treatment Type USD Million (2024-2029)
  • Table 189. China Multiple Sclerosis, by Drug Class USD Million (2024-2029)
  • Table 190. Japan Multiple Sclerosis, by Type USD Million (2024-2029)
  • Table 191. Japan Multiple Sclerosis, by Distribution Channel USD Million (2024-2029)
  • Table 192. Japan Multiple Sclerosis, by Treatment Type USD Million (2024-2029)
  • Table 193. Japan Multiple Sclerosis, by Drug Class USD Million (2024-2029)
  • Table 194. India Multiple Sclerosis, by Type USD Million (2024-2029)
  • Table 195. India Multiple Sclerosis, by Distribution Channel USD Million (2024-2029)
  • Table 196. India Multiple Sclerosis, by Treatment Type USD Million (2024-2029)
  • Table 197. India Multiple Sclerosis, by Drug Class USD Million (2024-2029)
  • Table 198. South Korea Multiple Sclerosis, by Type USD Million (2024-2029)
  • Table 199. South Korea Multiple Sclerosis, by Distribution Channel USD Million (2024-2029)
  • Table 200. South Korea Multiple Sclerosis, by Treatment Type USD Million (2024-2029)
  • Table 201. South Korea Multiple Sclerosis, by Drug Class USD Million (2024-2029)
  • Table 202. Taiwan Multiple Sclerosis, by Type USD Million (2024-2029)
  • Table 203. Taiwan Multiple Sclerosis, by Distribution Channel USD Million (2024-2029)
  • Table 204. Taiwan Multiple Sclerosis, by Treatment Type USD Million (2024-2029)
  • Table 205. Taiwan Multiple Sclerosis, by Drug Class USD Million (2024-2029)
  • Table 206. Australia Multiple Sclerosis, by Type USD Million (2024-2029)
  • Table 207. Australia Multiple Sclerosis, by Distribution Channel USD Million (2024-2029)
  • Table 208. Australia Multiple Sclerosis, by Treatment Type USD Million (2024-2029)
  • Table 209. Australia Multiple Sclerosis, by Drug Class USD Million (2024-2029)
  • Table 210. Rest of Asia-Pacific Multiple Sclerosis, by Type USD Million (2024-2029)
  • Table 211. Rest of Asia-Pacific Multiple Sclerosis, by Distribution Channel USD Million (2024-2029)
  • Table 212. Rest of Asia-Pacific Multiple Sclerosis, by Treatment Type USD Million (2024-2029)
  • Table 213. Rest of Asia-Pacific Multiple Sclerosis, by Drug Class USD Million (2024-2029)
  • Table 214. Europe Multiple Sclerosis, by Country USD Million (2024-2029)
  • Table 215. Europe Multiple Sclerosis, by Type USD Million (2024-2029)
  • Table 216. Europe Multiple Sclerosis, by Distribution Channel USD Million (2024-2029)
  • Table 217. Europe Multiple Sclerosis, by Treatment Type USD Million (2024-2029)
  • Table 218. Europe Multiple Sclerosis, by Drug Class USD Million (2024-2029)
  • Table 219. Germany Multiple Sclerosis, by Type USD Million (2024-2029)
  • Table 220. Germany Multiple Sclerosis, by Distribution Channel USD Million (2024-2029)
  • Table 221. Germany Multiple Sclerosis, by Treatment Type USD Million (2024-2029)
  • Table 222. Germany Multiple Sclerosis, by Drug Class USD Million (2024-2029)
  • Table 223. France Multiple Sclerosis, by Type USD Million (2024-2029)
  • Table 224. France Multiple Sclerosis, by Distribution Channel USD Million (2024-2029)
  • Table 225. France Multiple Sclerosis, by Treatment Type USD Million (2024-2029)
  • Table 226. France Multiple Sclerosis, by Drug Class USD Million (2024-2029)
  • Table 227. Italy Multiple Sclerosis, by Type USD Million (2024-2029)
  • Table 228. Italy Multiple Sclerosis, by Distribution Channel USD Million (2024-2029)
  • Table 229. Italy Multiple Sclerosis, by Treatment Type USD Million (2024-2029)
  • Table 230. Italy Multiple Sclerosis, by Drug Class USD Million (2024-2029)
  • Table 231. United Kingdom Multiple Sclerosis, by Type USD Million (2024-2029)
  • Table 232. United Kingdom Multiple Sclerosis, by Distribution Channel USD Million (2024-2029)
  • Table 233. United Kingdom Multiple Sclerosis, by Treatment Type USD Million (2024-2029)
  • Table 234. United Kingdom Multiple Sclerosis, by Drug Class USD Million (2024-2029)
  • Table 235. Netherlands Multiple Sclerosis, by Type USD Million (2024-2029)
  • Table 236. Netherlands Multiple Sclerosis, by Distribution Channel USD Million (2024-2029)
  • Table 237. Netherlands Multiple Sclerosis, by Treatment Type USD Million (2024-2029)
  • Table 238. Netherlands Multiple Sclerosis, by Drug Class USD Million (2024-2029)
  • Table 239. Rest of Europe Multiple Sclerosis, by Type USD Million (2024-2029)
  • Table 240. Rest of Europe Multiple Sclerosis, by Distribution Channel USD Million (2024-2029)
  • Table 241. Rest of Europe Multiple Sclerosis, by Treatment Type USD Million (2024-2029)
  • Table 242. Rest of Europe Multiple Sclerosis, by Drug Class USD Million (2024-2029)
  • Table 243. MEA Multiple Sclerosis, by Country USD Million (2024-2029)
  • Table 244. MEA Multiple Sclerosis, by Type USD Million (2024-2029)
  • Table 245. MEA Multiple Sclerosis, by Distribution Channel USD Million (2024-2029)
  • Table 246. MEA Multiple Sclerosis, by Treatment Type USD Million (2024-2029)
  • Table 247. MEA Multiple Sclerosis, by Drug Class USD Million (2024-2029)
  • Table 248. Middle East Multiple Sclerosis, by Type USD Million (2024-2029)
  • Table 249. Middle East Multiple Sclerosis, by Distribution Channel USD Million (2024-2029)
  • Table 250. Middle East Multiple Sclerosis, by Treatment Type USD Million (2024-2029)
  • Table 251. Middle East Multiple Sclerosis, by Drug Class USD Million (2024-2029)
  • Table 252. Africa Multiple Sclerosis, by Type USD Million (2024-2029)
  • Table 253. Africa Multiple Sclerosis, by Distribution Channel USD Million (2024-2029)
  • Table 254. Africa Multiple Sclerosis, by Treatment Type USD Million (2024-2029)
  • Table 255. Africa Multiple Sclerosis, by Drug Class USD Million (2024-2029)
  • Table 256. North America Multiple Sclerosis, by Country USD Million (2024-2029)
  • Table 257. North America Multiple Sclerosis, by Type USD Million (2024-2029)
  • Table 258. North America Multiple Sclerosis, by Distribution Channel USD Million (2024-2029)
  • Table 259. North America Multiple Sclerosis, by Treatment Type USD Million (2024-2029)
  • Table 260. North America Multiple Sclerosis, by Drug Class USD Million (2024-2029)
  • Table 261. United States Multiple Sclerosis, by Type USD Million (2024-2029)
  • Table 262. United States Multiple Sclerosis, by Distribution Channel USD Million (2024-2029)
  • Table 263. United States Multiple Sclerosis, by Treatment Type USD Million (2024-2029)
  • Table 264. United States Multiple Sclerosis, by Drug Class USD Million (2024-2029)
  • Table 265. Canada Multiple Sclerosis, by Type USD Million (2024-2029)
  • Table 266. Canada Multiple Sclerosis, by Distribution Channel USD Million (2024-2029)
  • Table 267. Canada Multiple Sclerosis, by Treatment Type USD Million (2024-2029)
  • Table 268. Canada Multiple Sclerosis, by Drug Class USD Million (2024-2029)
  • Table 269. Mexico Multiple Sclerosis, by Type USD Million (2024-2029)
  • Table 270. Mexico Multiple Sclerosis, by Distribution Channel USD Million (2024-2029)
  • Table 271. Mexico Multiple Sclerosis, by Treatment Type USD Million (2024-2029)
  • Table 272. Mexico Multiple Sclerosis, by Drug Class USD Million (2024-2029)
  • Table 273. Research Programs/Design for This Report
  • Table 274. Key Data Information from Secondary Sources
  • Table 275. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Multiple Sclerosis: by Type USD Million (2018-2023)
  • Figure 5. Global Multiple Sclerosis: by Distribution Channel USD Million (2018-2023)
  • Figure 6. Global Multiple Sclerosis: by Treatment Type USD Million (2018-2023)
  • Figure 7. Global Multiple Sclerosis: by Drug Class USD Million (2018-2023)
  • Figure 8. South America Multiple Sclerosis Share (%), by Country
  • Figure 9. Asia Pacific Multiple Sclerosis Share (%), by Country
  • Figure 10. Europe Multiple Sclerosis Share (%), by Country
  • Figure 11. MEA Multiple Sclerosis Share (%), by Country
  • Figure 12. North America Multiple Sclerosis Share (%), by Country
  • Figure 13. Global Multiple Sclerosis share by Players 2023 (%)
  • Figure 14. Global Multiple Sclerosis share by Players (Top 3) 2023(%)
  • Figure 15. Global Multiple Sclerosis share by Players (Top 5) 2023(%)
  • Figure 16. BCG Matrix for key Companies
  • Figure 17. Roche Holding AG(Switzerland) Revenue, Net Income and Gross profit
  • Figure 18. Roche Holding AG(Switzerland) Revenue: by Geography 2023
  • Figure 19. Biogen Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 20. Biogen Inc. (United States) Revenue: by Geography 2023
  • Figure 21. Novartis AG (Switzerland) Revenue, Net Income and Gross profit
  • Figure 22. Novartis AG (Switzerland) Revenue: by Geography 2023
  • Figure 23. Teva Pharmaceutical Industries Ltd. (Israel) Revenue, Net Income and Gross profit
  • Figure 24. Teva Pharmaceutical Industries Ltd. (Israel) Revenue: by Geography 2023
  • Figure 25. Elan Corporation plc (Ireland) Revenue, Net Income and Gross profit
  • Figure 26. Elan Corporation plc (Ireland) Revenue: by Geography 2023
  • Figure 27. Johnson & Johnson Services, Inc (United States) Revenue, Net Income and Gross profit
  • Figure 28. Johnson & Johnson Services, Inc (United States) Revenue: by Geography 2023
  • Figure 29. AbbVie Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 30. AbbVie Inc. (United States) Revenue: by Geography 2023
  • Figure 31. Mitsubishi Tanabe Pharma Corporation (Japan) Revenue, Net Income and Gross profit
  • Figure 32. Mitsubishi Tanabe Pharma Corporation (Japan) Revenue: by Geography 2023
  • Figure 33. Sanofi (France) Revenue, Net Income and Gross profit
  • Figure 34. Sanofi (France) Revenue: by Geography 2023
  • Figure 35. Merck KGaA (Germany) Revenue, Net Income and Gross profit
  • Figure 36. Merck KGaA (Germany) Revenue: by Geography 2023
  • Figure 37. Global Multiple Sclerosis: by Type USD Million (2024-2029)
  • Figure 38. Global Multiple Sclerosis: by Distribution Channel USD Million (2024-2029)
  • Figure 39. Global Multiple Sclerosis: by Treatment Type USD Million (2024-2029)
  • Figure 40. Global Multiple Sclerosis: by Drug Class USD Million (2024-2029)
  • Figure 41. South America Multiple Sclerosis Share (%), by Country
  • Figure 42. Asia Pacific Multiple Sclerosis Share (%), by Country
  • Figure 43. Europe Multiple Sclerosis Share (%), by Country
  • Figure 44. MEA Multiple Sclerosis Share (%), by Country
  • Figure 45. North America Multiple Sclerosis Share (%), by Country
List of companies from research coverage that are profiled in the study
  • Roche Holding AG(Switzerland)
  • Biogen Inc. (United States)
  • Novartis AG (Switzerland)
  • Teva Pharmaceutical Industries Ltd. (Israel)
  • Elan Corporation plc (Ireland)
  • Johnson & Johnson Services, Inc (United States)
  • AbbVie Inc. (United States)
  • Mitsubishi Tanabe Pharma Corporation (Japan)
  • Sanofi (France)
  • Merck KGaA (Germany)
Additional players considered in the study are as follows:
Siemens Healthineers (Germany) , EMD Serono (United States) , Philips Healthcare (Netherlands) , Bio-Rad Laboratories, Inc. (United States) , LabCorp (United States) , Rehman Technology Consulting, LLC (United States)
Select User Access Type

Key Highlights of Report


Jan 2024 203 Pages 92 Tables Base Year: 2023 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Multiple Sclerosis Market Quantitative research analysis
Global Multiple Sclerosis Market Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The standard version of the report profiles players such as Roche Holding AG(Switzerland), Biogen Inc. (United States), Novartis AG (Switzerland), Teva Pharmaceutical Industries Ltd. (Israel), Elan Corporation plc (Ireland), Johnson & Johnson Services, Inc (United States), AbbVie Inc. (United States), Mitsubishi Tanabe Pharma Corporation (Japan), Sanofi (France) and Merck KGaA (Germany) etc.
The Study can be customized subject to feasibility and data availability. Please connect with our sales representative for further information.
"Growing Role of Artificial Intelligence in medical data, predicting disease progression, and identifying potential drug targets." is seen as one of major influencing trends for Multiple Sclerosis Market during projected period 2023-2029.
The Multiple Sclerosis market study includes a random mix of players, including both market leaders and some top growing emerging players. Connect with our sales executive to get a complete company list in our research coverage.
Analysts at AMA estimates Multiple Sclerosis Market to reach USD35160.0 Million by 2029.

Know More About Global Multiple Sclerosis Market Report?

Have a Query? Click Here

Other Related Reports

Folinic Acid Comprehensive Study by Application (Hospitals, Pharmaceuticals, Nutraceutical, Food and Beverages, Others), Form (Tablets, Injection, Others), Distribution Channels (Online, Offline) Pla...
$ 3500
Ipecac Comprehensive Study by Type (Powder, Liquid (Syrup)), Application (Hospitals, Clinics), Distribution Channel (Online, Offline) Players and Region - Global Market Outlook to 2024
$ 3500
Kidney Detox Comprehensive Study by Type (Tablets, Capsules), Distribution Channel (Direct sales, Indirect sales), Industry Segmentation (Hospitals, Individuals) Players and Region - Global Market O...
$ 3500
Betaxolol Comprehensive Study by Form (Solution/Suspension, Film-Coated Tablets), Distribution Channels (Hospitals, Medical Pharmacy, Online Medical Store), Disease Indication (Glaucoma, Hypertension...
$ 3350
Citrus Bioflavonoids Comprehensive Study by Type (Conventional, Organic), Application (Pharmaceuticals & dietary supplements, Food & beverages, Animal feed, Cosmetics & Personal care), Products (Hesp...
$ 3650
Rapamune (Sirolimus) Comprehensive Study by Application (Organ Transplant Rejection, Lymphangioleiomyomatosis, Sirolimus Coated Balloons and Catheter Devices), Distribution Channel (Hospital Pharmaci...
$ 3650